 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Factors influencing time to viral rebound during analytical treatment interruptions in HIV cure trials (Room 13a/Channel 6) - Jun 18, 2024 - Abstract #AIDS2024AIDS_3973;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- || Istodax (romidepsin) / Astellas, BMS
Clinical, Journal: Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals. (Pubmed Central) - Mar 4, 2020
In these patients, romidepsin increased early events in HIV transcription (initiation and especially elongation), but had less effect on later stages (completion, multiple splicing) that may be required for comprehensive latency reversal and cell killing. Without cell death, increased HIV transcription before or after latency reversal may hasten viral rebound after therapy interruption.
- ||| Vacc-C5, Vacc-4x, Pro140, OyaGen HIV eradication, eCD4-Ig Farzan protein, FIT Biotech(now disappeared), Dermavir, N6 antibody, VRC01, SP-01A, VDA KP-1461 just to name a few. So honor history in the present! (Twitter) - Feb 22, 2020
- ||| Vacc-C5, Vacc-4x, Pro140, OyaGen HIV eradication, eCD4-Ig Farzan protein, FIT Biotech(now disappeared), Dermavir, N6 antibody, VRC01, SP-01A, VDA KP-1461 just to name a few. So are you serious or just playing propaganda? (Twitter) - Dec 3, 2019
- ||| Vacc-C5, Vacc-4x, Pro140, OyaGen HIV eradication, eCD4-Ig Farzan protein, FIT Biotech(now disappeared), Dermavir, N6 antibody, VRC01, SP-01A, VDA KP-1461 just to name a few. So are you serious or just playing propaganda? CURE NOW or shut up Gilead! (Twitter) - Nov 29, 2019
- | Vacc-4x / Bionor
Enrollment closed, Epigenetic controller: Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (clinicaltrials.gov) - Dec 9, 2014
P1/2, N=26, Active, not recruiting, Sponsor: Bionor Immuno AS
Without cell death, increased HIV transcription before or after latency reversal may hasten viral rebound after therapy interruption. Recruiting --> Active, not recruiting
- | Vacc-4x / Bionor
Enrollment change: Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=36, Completed, Sponsor: Bionor Immuno AS
Recruiting --> Active, not recruiting N=30 --> 36
- | Vacc-4x / Bionor
Trial completion: Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (clinicaltrials.gov) - Oct 10, 2014
P1/2, N=30, Completed, Sponsor: Bionor Immuno AS
N=30 --> 36 Active, not recruiting --> Completed
- Vacc-4x / Bionor
Trial primary completion date: Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (clinicaltrials.gov) - May 11, 2014
P1/2, N=36, Active, not recruiting, Sponsor: Bionor Immuno AS
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Aug 2014
- | Vacc-4x / Bionor
Enrollment closed: Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (clinicaltrials.gov) - May 11, 2014
P1/2, N=36, Active, not recruiting, Sponsor: Bionor Immuno AS
Trial primary completion date: Jun 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- | Vacc-4x / Bionor
New P1/2 trial, Epigenetic controller: Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (clinicaltrials.gov) - Mar 17, 2014
P1/2, N=26, Recruiting, Sponsor: Bionor Immuno AS
- | Vacc-4x / Bionor
Trial completion: Re-boosting of HIV-1 Infected Subjects With Vacc-4x (clinicaltrials.gov) - Jan 12, 2014
P2, N=33, Completed, Sponsor: Bionor Immuno AS
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Vacc-4x / Bionor
New P2 trial: Re-boosting of HIV-1 Infected Subjects With Vacc-4x (clinicaltrials.gov) - Oct 21, 2012
P2, N=33, Completed, Sponsor: Bionor Immuno AS
- | Vacc-4x / Bionor
New P1/2 trial: Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (clinicaltrials.gov) - Oct 9, 2012
P1/2, N=36, Recruiting, Sponsor: Bionor Immuno AS
- | Vacc-4x / Bionor
Enrollment open: Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (clinicaltrials.gov) - Oct 9, 2012
P1/2, N=36, Recruiting, Sponsor: Bionor Immuno AS
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Vacc-4x / Bionor
New P2 trial: Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical study (EUDRACT) - Aug 5, 2012
P2, N=40, Ongoing, Sponsor: Bionor Immuno AS`BIONOR IMMUNO AS
- Vacc-4x / Bionor
Trial completion: Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant (clinicaltrials.gov) - Jun 18, 2012
P1/2, N=24, Completed, Sponsor: Oslo University Hospital
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- Vacc-4x / Bionor
New P1/2 trial: Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant (clinicaltrials.gov) - Nov 15, 2011
P1/2, N=24, Completed, Sponsor: Oslo University Hospital